Stroke didn't have any progress for eons.
Press Release Source: AstraZeneca Hair loss
AstraZeneca Initiates Major Phase III Clinical Trials of CEROVIVE For Treatment of Patients with Acute Ischemic Stroke Tuesday May 27, 9:42 am ET
WILMINGTON, Del., May 27 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN - News) announced today the initiation of two major Phase III pivotal clinical trials to determine the effect of CEROVIVE (R) (also known as NXY-059) on disability and neurological recovery in acute ischemic stroke patients. The clinical trial program, known as the SAINT (Stroke - Acute Ischemic - NXY Treatment) Trials, will compare the efficacy and safety of a 72-hour intravenous infusion of CEROVIVE given within six hours of the onset of symptoms, versus placebo.
cerovive trademark of astrazenica
Two multinational, multicenter, double-blind, randomized, placebo- controlled parallel-group studies will be enrolling more than 3000 loss nu "Acute stroke is an area with substantial unmet need for new effective therapies," said Bill Bastain, Global Vice President, Neuroscience Research and Development, AstraZeneca. "AstraZeneca views acute stroke as a treatable emergency Phase I/II trials including two trials(3)(4) in acute stroke patients have been completed to determine the appropriate dose and tolerability of CEROVIVE. The data from the animal models and phase I/II trials have facilitated the initiation of the phase III trials of CEROVIVE in acute ischemic stroke.renovis,a registered trademark astrazeneca.
Hair loss treatment alopecia redox cellular signaling free radical superoxide nitrones nitrone nitroxide nitroxides conductive organic polymers semiconductors dismutase free radical
alopecia regrowth minoxidil peptides peptide propecia antiandrogen antiandrogensalopecia regrowth minoxidil peptides peptide propecia antiandrogen antiandrogens
redox signaling